|Videos|January 24, 2023
Prevalence of Hypothyroidism in a Commercially Insured US Population: Results by Region
An expert in hypothyroidism management reviews key prevalence data examined across US regions and examined by treatment type from a recent poster presentation highlighting the prevalence of hypothyroidism in a commercially insured US population.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
3
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5